Australija - anglų - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; hypromellose; microcrystalline cellulose; copovidone; magnesium stearate - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 750 mg - tablet, modified release - excipient ingredients: carmellose sodium; magnesium stearate; microcrystalline cellulose; copovidone; hypromellose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 750 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; copovidone; carmellose sodium; hypromellose; magnesium stearate - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; hypromellose; microcrystalline cellulose; magnesium stearate; copovidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

viatris limited - metformin hydrochloride 500mg;   - film coated tablet - 500 mg - active: metformin hydrochloride 500mg   excipient: hypromellose magnesium stearate povidone

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

viatris limited - metformin hydrochloride 850mg;   - film coated tablet - 850 mg - active: metformin hydrochloride 850mg   excipient: hypromellose magnesium stearate povidone

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glipizide 2.5 mg - glipizide and metformin hcl tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide and metformin hcl tablets are contraindicated in patients with: 1. severe renal impairment (egfr below 30 ml/min/1.73 m2 ) (see warnings and precautions ). 2. known hypersensitivity to glipizide or metformin hydrochloride. 3. acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

remedyrepack inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glipizide and metformin hcl tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide and metformin hcl tablets are contraindicated in patients with: 1. severe renal impairment (egfr below 30 ml/min/1.73 m 2 ) (see warnings and precautions ). 2. known hypersensitivity to glipizide or metformin hydrochloride. 3. acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

remedyrepack inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glipizide and metformin hcl tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide and metformin hcl tablets are contraindicated in patients with: 1. severe renal impairment (egfr below 30 ml/min/1.73 m 2 ) (see warnings and precautions ). 2. known hypersensitivity to glipizide or metformin hydrochloride. 3. acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin.

Singapūras - anglų - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - metformin 780mg eqv to metformin hydrochloride; sitagliptin phosphate 128.5mg eqv to sitagliptin - tablet, film coated, extended release - metformin 780mg eqv to metformin hydrochloride 1000mg; sitagliptin phosphate 128.5mg eqv to sitagliptin 100 mg